Self-Experimenting Virologist Defeats Breast Cancer With Lab-Grown Virus Treatment

A University of Zagreb virologist treated her own recurring breast cancer by injecting laboratory-grown viruses into her tumor, sparking debate about self-experimentation in medical research. Beata Halassy discovered her stage 3 breast cancer in 2020 at age 49, recurring at the site of a previous mastectomy. Rather than undergo another round of chemotherapy, she developed an experimental treatment using oncolytic virotherapy (OVT).

Over two months, Halassy administered measles and vesicular stomatitis viruses directly into the tumor. The treatment caused the tumor to shrink and detach from surrounding tissue before surgical removal. Post-surgery analysis showed immune cell infiltration, suggesting the viruses had triggered an immune response against the cancer. Halassy has been cancer-free for four years. OVT remains unapproved for breast cancer treatment worldwide. Nature adds: Halassy felt a responsibility to publish her findings. But she received more than a dozen rejections from journals -- mainly, she says, because the paper, co-authored with colleagues, involved self-experimentation. "The major concern was always ethical issues," says Halassy. She was particularly determined to persevere after she came across a review highlighting the value of self-experimentation.

That journals had concerns doesn't surprise Jacob Sherkow, a law and medicine researcher at the University of Illinois Urbana-Champaign who has examined the ethics of researcher self-experimentation in relation to COVID-19 vaccines. The problem is not that Halassy used self-experimentation as such, but that publishing her results could encourage others to reject conventional treatment and try something similar, says Sherkow. People with cancer can be particularly susceptible to trying unproven treatments. Yet, he notes, it's also important to ensure that the knowledge that comes from self-experimentation isn't lost. The paper emphasizes that self-medicating with cancer-fighting viruses "should not be the first approach" in the case of a cancer diagnosis.